Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies

BMC Cardiovascular Disorders

Research Article

Rui Guo¹  Guang Hao²  Zuo Chen²  Xin Wang²  Linfeng Zhang²  Zengwu Wang²  Wei Li³ 

[1] Chinese medical association publishing house, No.42 Dongsi Street Dongcheng District, 100037, Beijing, China;Division of Prevention & Community Health, National Center for Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, No. 167 Beilishi Road Xicheng District, 100037, Beijing, China;National Center for Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, No. 167 Beilishi Road Xicheng District, 100037, Beijing, China;

关键词: Hypertensive Patient;    Valsartan;    Fosinopril;    Captopril Prevention Project;    Irbesartan Diabetic Nephropathy Trial;   

DOI  :  10.1186/1471-2261-14-148

 received in 2014-08-08, accepted in 2014-10-17,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundThe effects of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) on cardiovascular (CV) risk in hypertensive patients with type 2 diabetes mellitus (T2 DM) are uncertain. Our objective was to analyze the effects of ACE/ARBs, on the incidence of myocardial infarction, stroke, CV events, and all-cause mortality in hypertensive patients with T2 DM.MethodPubMed and Embase databases were searched through January 2014 to identify studies meeting a priori inclusion criteria and references in the published articles were also reviewed. Two investigators independently extracted the information with either fixed-effect model or random-effect model to assess the effects of ACE/ARBs treatment in hypertensive patients with T2 DM.ResultsTen randomized controlled studies were included with a total of 21,871 participants. Overall, treatment with ACE/ARBs in hypertensive patients with T2 DM was associated with a statistically significant 10% reduction in CV events, pooled hazard ratio (HR) of 0.90 [95% confidence intervals (CI): 0.82-0.98] with no heterogeneity (I2 = 19.50%; P = 0.275);and 17% reduction in CV mortality, pooled HR of 0.83 [95% CI: 0.72-0.96] with no heterogeneity (I2 = 0.9%; P = 0.388). ACE/ARBs was not associated with MI, stroke and all-cause mortality.ConclusionsTreatment with ACE/ARBs results in significant reduction in CV events and mortality in hypertensive patients with T2 DM.

【 授权许可】

Unknown   
© Hao et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.